Business Wire

06 Jun 2026, 20:45 UTC · 3h ago

Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®

Read original · https://www.businesswire.com/news/home/20260606758364/en/Corcept-Presents-New-Data-at-ADA-Improved-Outcomes-in-Patients-Receiving-a-GLP-1-with-Difficult-to-Control-Type-2-Diabetes-and-Hypercortisolism-Treated-with-Korlym%C2%AE/

Top 2 movers · tap to explore

Story key points

0 claims · impact-rated

What matters in this story

No key-points head found for this article.

Ticker attribution

Model heads

Sentiment in this article

CORT+0.60
The company is presenting new data from clinical trials at a major scientific session, which typically serves as a positive catalyst.

Relationships in this article

No ticker relationship head found.

Early access

You’re reading about it. Someone else is already positioned.

News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.

CORT

Browse live screenings

Impact vectors

1 dimensions · 9 clusters

Analytical profile by cluster

Sector Rotation

6 related stories

GuruFocus
5h ago
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i
- clinical trials
- diabetes
Read

Corcept Presents New Data at ADA: Improved Outcomes in Patients Recei… · News Impact Screener

Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Analytical profile by cluster

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i

Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Analytical profile by cluster

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i

Top impact dimensions

Most positively impacted

Most negatively impacted

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions

Medicus Pharma advances SkinJect for Gorlin syndrome – ICYMI

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide

Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Analytical profile by cluster

Next reads from the same story arc

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i

Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Analytical profile by cluster

Next reads from the same story arc

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i

Top impact dimensions

Most positively impacted

Most negatively impacted

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions

Medicus Pharma advances SkinJect for Gorlin syndrome – ICYMI

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide